Welcome to our dedicated page for United Therapeutics news (Ticker: UTHR), a resource for investors and traders seeking the latest updates and insights on United Therapeutics stock.
United Therapeutics Corporation (UTHR) delivers innovative therapies for pulmonary arterial hypertension and rare diseases through cutting-edge research and targeted drug development. This news hub provides investors, healthcare professionals, and stakeholders with timely updates on regulatory milestones, clinical trial progress, and strategic initiatives shaping the biopharmaceutical landscape.
Access verified press releases, financial disclosures, and scientific advancements in one centralized location. Our curated collection features updates on treprostinil-based treatments, FDA approvals, partnership announcements, and R&D pipeline developments – all essential for tracking UTHR's progress in addressing unmet medical needs.
Discover comprehensive coverage spanning earnings reports, manufacturing expansions, and therapeutic innovations. Content is rigorously vetted to ensure accuracy and relevance for both expert analysts and general readers seeking reliable information about this biotechnology leader.
Bookmark this page for streamlined access to United Therapeutics' latest developments. Check back regularly to stay informed about critical updates impacting patient care and investment considerations in the specialized pharmaceutical sector.
United Therapeutics (Nasdaq: UTHR) announced significant advancements in xenotransplantation with the world's first genetically-modified heart transplant (UHeart™) reaching a two-week milestone, showcasing normal organ function. Additionally, the UKidney™ procedure's data was published in the American Journal of Transplantation, marking a first in peer-reviewed studies. The UThymoKidney™ was noted for its historic preclinical study, furthering the quest for sustainable organ supply. These innovations reinforce United Therapeutics' commitment to transforming organ transplantation and improving patient outcomes.
United Therapeutics Corporation (Nasdaq: UTHR) announced that Martine Rothblatt, Ph.D., and Michael Benkowitz will engage in a fireside chat hosted by J.P. Morgan's biotech analyst, Jessica Fye. This virtual event is scheduled for January 6, 2022, from 8:00 a.m. to 8:45 a.m. EST, featuring updates on the company’s mission and business. Access will be through a live webcast, with an archived version available after the session. The company continues to pioneer treatments for pulmonary arterial hypertension and aims to expand organ transplant availability.
United Therapeutics announced a 17% increase in total revenue for Q3 2021, reaching $444.7 million compared to $380.1 million in Q3 2020. Net income fell 5% to $162.7 million, with non-GAAP earnings rising 14% to $198 million. The company highlighted a growing patient base for its Tyvaso therapy, now with approximately 4,000 patients in the USA. Additionally, progress in six phase 3 clinical trials was noted, indicating a robust pipeline for pulmonary hypertension treatments.
United Therapeutics Corporation (Nasdaq: UTHR) will present an update on its business at the Credit Suisse 30th Annual Healthcare Conference on November 8, 2021, from 8:50 a.m. to 9:30 a.m. EST. Michael Benkowitz, President and COO, will lead the discussion. The session will be available via live webcast on the company's website, with an archived version accessible 24 hours post-event for 90 days. United Therapeutics aims to cure pulmonary arterial hypertension and is notable for being the first publicly-traded company structured as a public benefit corporation.
Volumetric, a Houston-based biofabrication start-up, has been acquired by 3D Systems (NYSE: DDD) for an initial payment of
United Therapeutics Corporation (Nasdaq: UTHR) has announced it will release its third quarter 2021 financial results on November 3, 2021, before the market opens. A public webcast will take place on the same day at 9:00 a.m. Eastern Time, accessible via the company's website. The company focuses on finding a cure for pulmonary arterial hypertension and has received FDA approval for five medications. United Therapeutics operates as a public benefit corporation, aiming to enhance shareholder value while promoting sustainability and healthcare advancements.
On October 21, 2021, United Therapeutics (Nasdaq: UTHR) presented significant clinical data at CHEST 2021 regarding pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The highlight was the new pharmacokinetic data from the BREEZE study of Tyvaso DPI, which showed comparable systemic exposure to existing Tyvaso treatments with reduced variability. The data indicate successful transitions from Tyvaso to Tyvaso DPI, enhancing patient outcomes, such as improved walking distance and overall satisfaction.
United Therapeutics Corporation (Nasdaq: UTHR) announced a setback in the FDA review of its new drug application for Tyvaso DPI™ for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). On October 15, 2021, the FDA issued a complete response letter citing a single deficiency at a third-party testing facility, delaying approval. The company aims to resolve this issue and anticipates resubmission by summer 2022.
United Therapeutics Corporation (Nasdaq: UTHR) announced the presentation of new data on pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) at the CHEST 2021 meeting, scheduled for October 17-20, 2021. The company will showcase 10 abstracts, including pharmacokinetic data from the BREEZE study of Tyvaso DPI™. This study involved 51 PAH patients and aimed to assess the safety and tolerability of Tyvaso DPI. Highlights also include real-world analyses of Orenitram and implications for patient care.
FAQ
What is the current stock price of United Therapeutics (UTHR)?
What is the market cap of United Therapeutics (UTHR)?
